Stanford University Medical Center, Department of Pediatrics, Division of Nephrology, 300 Pasteur Drive, Room G-306, Stanford, CA 94035, USA.
Nephrol Dial Transplant. 2010 Dec;25(12):4048-54. doi: 10.1093/ndt/gfq295. Epub 2010 May 25.
Peritonitis is a common complication of chronic peritoneal dialysis (CPD) and can be associated with technique failure. Enterococcus is an uncommon peritoneal pathogen in children receiving CPD but represents a potential therapeutic challenge due to its innate resistance to cephalosporins and emerging resistance to glycopeptides.
The International Pediatric Peritonitis Registry is a global consortium of 47 paediatric dialysis centres designed to address validation of the International Society for Peritoneal Dialysis paediatric peritonitis treatment guidelines. Between 2001 and 2004, peritonitis episodes were assessed in 392 participating children receiving CPD.
Among the 392 patients, 340 episodes of culture-positive peritonitis were evaluated. Twenty of these episodes were due to Enterococcus species (5.9%). There were no clinical characteristics uniquely associated with enterococcal peritonitis at presentation. After 3 days of therapy, 75% of patients were pain free, 95% had decreased effluent cloudiness and 90% were afebrile. Only one patient required a catheter exchange, and all patients experienced full functional recovery. Despite broad in vitro resistance to cephalosporins and 21% resistance to glycopeptides, neither in vitro resistance pattern nor choice of empiric antibiotic regimen affected short- or long-term outcomes.
Enterococci are likely responsible for ∼6% of culture-positive peritonitis episodes in children receiving CPD. Although it was not possible to identify patients with enterococcal peritonitis based on presentation, clinical response was not associated with in vitro resistance patterns, and patients who initially received a cephalosporin-based empiric regimen until culture results are available are likely to respond quickly and have full functional recovery.
腹膜炎是慢性腹膜透析(CPD)的常见并发症,并可能与技术失败有关。肠球菌在接受 CPD 的儿童中是一种不常见的腹膜病原体,但由于其对头孢菌素的固有耐药性和对糖肽类药物的新兴耐药性,它代表了一个潜在的治疗挑战。
国际儿科腹膜炎登记处是一个由 47 个儿科透析中心组成的全球联盟,旨在解决国际腹膜透析学会儿科腹膜炎治疗指南的验证问题。在 2001 年至 2004 年期间,对 392 名接受 CPD 的参与儿童的腹膜炎发作进行了评估。
在 392 名患者中,评估了 340 例培养阳性腹膜炎发作。其中 20 例是肠球菌属引起的(5.9%)。在出现时,没有与肠球菌性腹膜炎独特相关的临床特征。经过 3 天的治疗,75%的患者疼痛缓解,95%的患者流出液混浊度降低,90%的患者无发热。只有 1 名患者需要更换导管,所有患者均完全恢复功能。尽管对头孢菌素的体外耐药广泛,对糖肽类药物的耐药率为 21%,但体外耐药模式和经验性抗生素方案的选择均未影响短期或长期结局。
肠球菌可能导致接受 CPD 的儿童约 6%的培养阳性腹膜炎发作。尽管无法根据临床表现识别出肠球菌性腹膜炎患者,但临床反应与体外耐药模式无关,并且最初接受头孢菌素经验性治疗方案直到培养结果可用的患者可能会迅速反应并完全恢复功能。